
The purpose of the study was to determine if economic benefits result when cancer clinical trial patients receive zzso drug, thereby avoiding standard care drug costs for which institutions are financially zzso All open, closed and terminated zzso trial protocols and drug zzso data from zzso were reviewed for the zzso zzso zzso zzso and gynecology tumor groups at the Tom Baker Cancer zzso zzso and projected, potential drug cost avoidance per patient and per drug from the trials was zzso zzso percent of the 101 reviewed studies offered drug cost zzso Drug specific cost avoidance ranged from zzso to zzso per patient, while potential drug specific cost avoidance ranged from zzso to zzso per zzso zzso drug cost zzso according to tumor group, were calculated showing a median range of zzso to zzso per patient between tumor zzso The median range for potential drug cost avoidance was substantially higher, from zzso to zzso per zzso Economic benefits result for the institution when patients participating in clinical trials receive drug provided by an external zzso Drug cost avoidance varies due to type and cost of standard of care drug used and due to the design of individual zzso The existence of drug cost avoidance is an additional benefit that clinical trials can bring to an institution (in our case, zzso Health zzso 

